Upscaling & Transferring Manufacturing of an Allogeneic Active Immune Therapy in Preparation for Commercialization
Time: 10:30 am
day: Day Two - Track B AM
Details:
- Discussing key strategies to upscale manufacturing of an allogeneic dendritic cell cancer vaccine by partnering with CDMOs
- Vididencel is a maintenance immunotherapy designed to improve relapse-free and overall survival in AML
- Sharing strategies for a smooth tech transfer to take product manufacture to a larger level
